All News

pregnancy,embryo,fetal

Good Outcomes with TNF Blocker Use During RA Pregnancies

d Jack Cush, MD

A prospective cohort study of treatment and pregnancy outcomes in women with RA shows that TNF inhibitor use during pregnancy did not increase the risk of adverse pregnancy outcomes, but instead led to more positive outcomes such as fewer low-birth-weight deliveries.

Read Article
morbidity,covid,heart,lung,brain

No Special Heart Risk With JAK Inhibitors, Study Finds

d MedPage Today

Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.

Read Article
infusion.biologic.jpg

Intravenous Immune Globulin in Dermatomyositis

d Jack Cush, MD

Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this pivotal trial.

Read Article
Biomedical researchers are at their most creative/innovative EARLY in their career. Study based on 5.6 million papers (1980 to 2009). While least innovative drop out early; in the remaining, innovativeness tends to decline over their career.https://t.co/XY5xQfY8Ba https://t.co/Cs3MUr7qIi

Links:

Dr. John Cush RheumNow ( View Tweet)
Large retrospective claims data analysis of 86 964 adults w/ severe obesity and NAFLD: comparing bariatric surgery (35%) to those with nonsurgical care. Bariatric surgery lowered the risk of CVD by 49% https://t.co/xEVVQVEX30 https://t.co/gSUIeH1K0k

Links:

Dr. John Cush RheumNow ( View Tweet)

2 HIV+ pts with HLH (MAS) successfully Rx w/ JAKi - ruxolitinib. Both had high fevers, severe pancytopenia, hypofibrinogenemia, hypertriglyceridemia, & increased ferritin, BMBx Hemophagocytosis, splenomegaly. https://t.co/yGs7e4Ftgp https://t.co/cv9NX31bZr

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR suggests a new ICD-10 code for "Pre-clinical RA".(PROPOSED NEW CODE: R76.81 “Abnormal rheumatoid arthritis-related immunologic findings without current or prior diagnosis of clinically apparent inflammatory arthritis.” This is not yet final. https://t.co/2Td0lYiUKg https://t.co/8m2OSfPWXz

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center use IL-23 inhibitors (Guselkumab, Tildrakizumab, Risankizumab) in 80 PsA pts shows 1 yr survival 81%, w/ mean survival 61 wks (despite 95% Rx ≥1 prior biologics). 64% had PASI ≤2 at wks 12-17 and nearly 41% w/ PsA remission https://t.co/woDXhL44d5 https://t.co/6fvjzGlMEY

Links:

Dr. John Cush RheumNow ( View Tweet)
Record a Question or Comment... Rheums: Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/rICbSJzPbk https://t.co/VIjlR6xlwQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofacitinib shows promise in scleroderma https://t.co/6qUGLlztBd https://t.co/Mk2x2HAkiO

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow. https://t.co/EGXslouPmC https://t.co/UVcdjzbxYp

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/givh5j3m9z https://t.co/ms97tvQy5e

Links:

Dr. John Cush RheumNow ( View Tweet)
Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/2svMMX4wDw https://t.co/zoSGGZJYui

Links:

Dr. John Cush RheumNow ( View Tweet)
8 pts w/ Refractory Skin Dermatomyositis Rx w/ open label APREMILAST, @ 3 mos 7/8 pts responded w/ drop in CDASI (-12.9 pts; P < .001). Skin Bx showed downregulation of multiple inflamm pathways (STAT1/3, IL-4), IL-6, IL-12, IL-23, IFNγ & TNFα) https://t.co/mLElrRgFF1 https://t.co/4eidnPYdXJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Transitioning JIA to Adult Care is Problematic Juvenile idiopathic arthritis (JIA) may start in adolescence and extend into adulthood. This report shows that rheums need to develop "transition" practices to avoid a gap in healthcare. https://t.co/DV8BZjcP5e https://t.co/e1rFXWSmXN

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Arthritis Patients Need to Quit Smoking ASAP A report from an early arthritis registry shows that current smoking increases disease activity and lowers health-related quality of life. https://t.co/04WeK1OlRw https://t.co/yjZQdsrKsH

Links:

Dr. John Cush RheumNow ( View Tweet)
The University Of Pennsylvania has recv a $50 Million Gift (from Stewart & Judy Colton) to further develop the Autoimmune Disease Research program at Penn’s Colton Center for Autoimmunity. 6.4% of women and 2.7% of men have autoimmune disease https://t.co/7kdTiZnmiD https://t.co/5yXZTzmRM0

Links:

Dr. John Cush RheumNow ( View Tweet)
Causes of Death in Lupus The California Lupus Surveillance Project has longitudinally followed included SLE cases and shown that overall, the leading cause of death was CVD, followed by rheumatic disease and hematologic/oncologic conditions. https://t.co/XRtD2Rr77j https://t.co/fzVGSeQGQu

Links:

Dr. John Cush RheumNow ( View Tweet)
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/sR2OMNtxAk https://t.co/qOdMEZheFz

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow. https://t.co/eHKx2D0kKp https://t.co/UdC0k3hlmX

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×